Interferon Gamma ELISA Assay
The Interferon Gamma ELISA Assay is For Research Use Only
Size: 1×96 wells
Sensitivity: 7 pg/mL
Dynamic Range: 15.625-1000 pg/ml
Incubation Time: 3.5 hours
Sample Type: Serum, Plasma, Cell Culture
Sample Size: 100 µl
Alternative Names: IFN-gamma, IFN-γ
Interferon gamma (IFN-γ) is a multifunctional protein first observed as an antiviral activity in cultures of Sindbis virus-infected human leukocytes stimulated by PHA. Produced by Tlymphocytes and natural killer (NK) cells, IFN-γ is now known to be both an inhibitor of viral replication and a regulator of numerous immunological functions. Human IFN-γ is reported to be active only on human and non-human primate cells. The biochemistry and biological activities of the interferons have been extensively reviewed.
Human IFN-γ is a 143 amino acid residue, 20 or 25 kDa glycoprotein that demonstrates little sequence homology to IFN-α or –β. Naturally occurring IFN-γ is found as either of two molecular weight species, differing in degree of glycosylation. Human IFN-γ apparently exists as a head-to-tail dimer in solution with the C-terminus of one monomer aligned with the N-terminus of the other monomer.
A receptor for IFN-γ has been identified and its gene localized to chromosome 6 Apparently the product of a single gene, the receptor is a single chain 90 kDa glycoprotein that shows a high degree of species-specific binding of IFN-γ.
Functionally, IFN-γ produces a variety of effects. Produced by CD8+, NK, gd, and TH1 T helper cells, IFN-γ has documented antiviral, antiprotozoal and immunomodulatory effects on cell proliferation and apoptosis, as well as the stimulation and repression of a variety of genes he antiprotozoal activity of IFN-γ against Toxoplasma and Chlamydia is believed to result from indoleamine 2,3-dioxygenase activity, an enzyme induced by IFN-γ.The immunomodulatory effects of IFN-γ are extensive and diverse. In monocyte/macrophages, the activities of IFN-γ include: increasing the expression of class I and II MHC antigens; increasing the production of IL-1, platelet-activating factor, H2O2, and pterin; protection of monocytes against LAK cell-mediated lysis; downregulation of IL-8 mRNA expression that is upregulated by IL-2; and, with lipopolysaccharide, induction of NO production. Finally, IFN-γ has been shown to upregulate ICAM-1, but not E-Selectin or VCAM-1, expression on endothelial cells.
Mouse Interferon Gamma (IFN-gamma) ELISA Assay Kit
High Sensitive IFN gamma ELISA Assay Kit
The Eagle Biosciences Interferon Gamma (IFN-γ) ELISA Assay Kit employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for IFN-γ has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any IFN-γ present is bound by the immobilized antibody. Following incubation unbound samples are removed during a wash step, and then a detection antibody specific for IFN-γ is added to the wells and binds to the combination of capture antibody- IFN-γ in sample. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Following incubation and wash steps a substrate is added. A colored product is formed in proportion to the amount of IFN-γ present in the sample. The reaction is terminated by addition of acid and absorbance is measured at 450nm. A standard curve is prepared from seven IFN-γ standard dilutions and IFN-γ sample concentration determined.
- Prepare all reagents and working standards as directed in the previous sections.
- Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running blanks and standards. Remove extra microwell strips from holder and store in foil bag with the desiccant provided at 2-8°C sealed tightly.
- Add 100 µL of Standard, control, or sample, per well. Cover with the adhesive strip provided. Incubate for 1.5 hours at 37°C.
- Aspirate each well and wash, repeating the process three times for a total of four washes. Wash by filling each well with Wash Buffer (350 µL) using a squirt bottle, manifold dispenser or auto-washer. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining Wash Buffer by aspirating or decanting. Invert the plate and blot it against clean paper towels.
- Add 100 µL of the working solution of Biotin-Conjugate to each well. Cover with a new adhesive strip and incubate 1 hour at 37°C.
- Repeat the aspiration/wash.
- Add 100 µL of the working solution of Streptavidin-HRP to each well. Cover with a new adhesive strip and incubate for 30 minutes at 37°C. Avoid placing the plate in direct light.
- Repeat the aspiration/wash.
- Add 100 µL of Substrate Solution to each well. Incubate for 10-20 minutes at 37°C. Avoid placing the plate in direct light.
- Add 100 µL of Stop Solution to each well. Gently tap the plate to ensure thorough mixing.
- Determine the optical density of each well immediately, using a microplate reader set to 450 nm. (optionally 630nm as the reference wave length;610-650nm is acceptable)
Please note: All documents above are for reference use only and should not be used in place of the documents included with this physical product. If digital copies are needed, please contact us.
- Wheelock, E.F. (1965) Science 149:310.
- Ijzermans, J.M. and R.L. Marquet (1989) Immunobiol. 179:456.
- Mogensen, S.C. and J.L. Virelizier (1987) Interferon 8:55.
- Grossberg, S.E. et al. (1989) Experientia 45:508.
- Adolf, G.R. (1985) Oncology (Suppl. 1) 42:33.
- Samuel, C.E. (1991) Virology 183:1.
- Pellegrini, S. and C. Schindler (1993) Trends Biochem. Sci. 18:338.
- Reiter, Z. (1993) J. Interferon Res. 13:247.
- Boehm, U. et al. (1997) Annu. Rev. Immunol. 15:749.
- Gray, P.W. et al. (1982) Nature 295:503.
- Rinderknecht, E. et al. (1984) J. Biol. Chem. 259:6790.
- DeGrado, W.F. et al. (1982) Nature 300:379.
- Zoon, K.C. (1987) Interferon 9:1.
Abdel-Messeih, Phebe L., Neveen M. Nosseir, and Osama H. Bakhe. “Evaluation of inflammatory cytokines and oxidative stress markers in prostate cancer patients undergoing curative radiotherapy.” Central European Journal of Immunology1 (2017): 68-72. Web.